Searched for
NOVO NORDISK COMPETITORS
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...- Novo Nordisk plans to cut price of Ozempic as generics hit marketNovo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...
- Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- Eli Lilly becomes first healthcare firm to hit $1 trillion market cap - here’s why LLY stock has jumped over 36% this yearEli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...
- Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in IndiaAt a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- What’s powering Mounjaro’s rise to the top of Indian drug marketMounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...
- Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...
- Novo Nordisk's top investor seizes board controlIn a bold push for greater influence, a key investor in Novo Nordisk is advocating for a complete overhaul of the board. This strategic man...
- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- Mounjaro crosses Rs 50 cr in India in 90 days as Wegovy joins frayMounjaro, Eli Lilly's weight-loss drug, witnessed a massive sales jump in India since March. Sales reached ₹26 crore in June. Wegovy from N...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Pfizer scraps weight loss pill after liver injury: What it means for the future of obesity drugs?Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...
- US Justice Deptt charge against pharma cos a serious charge: Surajit Paul, Prabhudas Lilladher“In Sun-Taro’s case, they pushed up the price because there was not much competition or suppliers.”
- Companies like Eli Lilly, Biocon & Cadila oppose move to cut margin on insulinInsulin brands are set to appeal against the drug price regulator's decision to further squeeze their profit margins on the diabetes medici...
- Biocon keeps hopes of overseas sales under check"Any partner who looks at this asset will back-load the payment because while the market is huge, we still don't know if the drug works the...
- American firm Abbott consolidates top position in Indian drug marketAmerican firm Abbott Laboratories consolidated its top position in the Indian drug retail market by growing at a faster than its closest co...
- Market gives thumbs up to Biocon's deal with PfizerThe Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...
- Biocon seals Rs 1,550 cr pact with PfizerThe agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...
Load More
